Absci (ABSI) Income towards Parent Company (2020 - 2026)
Absci (ABSI) posted Income towards Parent Company of -$29.6 million for Q1 2026, little changed sequentially from -$29.6 million in Q4 2025, and down 12.35% YoY from -$33.8 million in Q1 2025.
Analysis
Absci (ABSI) Income towards Parent Company (2020 - 2026) Analysis & Trends
Absci has reported Income towards Parent Company for 7 years, with the latest figure at -$29.6 million in Q1 2026.
- Quarterly Income towards Parent Company fell 12.35% year-over-year to -$29.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$118.4 million (down 10.2% YoY) and the FY2025 annual result came in at -$115.2 million, down 11.71% from the prior year.
- Income towards Parent Company held at -$29.6 million in Q1 2026 per ABSI's latest filing, from -$29.6 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at -$19.5 million in Q4 2022 and troughed at -$41.7 million in Q2 2023.
- A 5-year average of -$27.3 million and a median of -$27.4 million in 2024 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2022 and 2024: Income towards Parent Company tumbled 169.62% in 2022, then jumped 40.61% in 2024.
- Over 5 years, Income towards Parent Company stood at -$19.5 million in 2022, then retreated by 20.92% to -$23.5 million in 2023, then decreased by 23.1% to -$29.0 million in 2024, then decreased by 2.0% to -$29.6 million in 2025, then retreated by 0.13% to -$29.6 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$29.6 million, -$29.6 million, and -$28.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.21 Bn | 132.36 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.73 Bn | 58.55 Bn | 1.37 Bn |
| 4 | Moderna | 57.59 Bn | 52.46 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 40.13 Bn | 35.04 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.55 Bn | 32.24 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.60 Bn | 27.77 Bn | - |
| 9 | Insmed | 27.70 Bn | 26.54 Bn | 358.27 Mn |
| 10 | Absci | 1.41 Bn | 1.21 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -33.21 Mn |
| Mar 31, 2026 | -29.60 Mn |
| Dec 31, 2025 | -29.56 Mn |
| Sep 30, 2025 | -28.71 Mn |
| Jun 30, 2025 | -30.57 Mn |
| Mar 31, 2025 | -26.35 Mn |
| Dec 31, 2024 | -28.98 Mn |
| Sep 30, 2024 | -27.40 Mn |
| Jun 30, 2024 | -24.75 Mn |
| Mar 31, 2024 | -21.98 Mn |
| Dec 31, 2023 | -23.55 Mn |
| Sep 30, 2023 | -21.99 Mn |
| Jun 30, 2023 | -41.67 Mn |
| Mar 31, 2023 | -23.36 Mn |
| Dec 31, 2022 | -19.47 Mn |
| Sep 30, 2022 | -27.26 Mn |
| Jun 30, 2022 | -28.68 Mn |
| Mar 31, 2022 | -29.49 Mn |
| Dec 31, 2021 | -25.17 Mn |
| Sep 30, 2021 | -23.63 Mn |